For sales

📢Highlights from the Week of September 1st – 8th, 2025 in the world of pharma and healthcare! 🗞️👀

VYUHPHARMA Highlights from the Week of September 01-08, 2025 NANOSCOPE THERAPEUTICS Nanoscope's MCO-010 therapy received FDA RMAT designation and five EMA Orphan designations, accelerating its development for a variety of retinal diseases MENARINI Menarini Group's obicetrapib and a combination therapy with ezetimibe have been accepted for review by the EMA for treating primary hypercholesterolaemia and mixed dyslipidaemia, supported by positive data from Ph3 trials IDEAVA BIOSCIENCES Servier and IDEAYA Biosciences have partnered to commercialize the eye cancer treatment darovasertib outside the US, with IDEAYA receiving a $210 million upfront payment and up to $320 million more in potential milestones (FDA, RMAT Designation, EMA, Orphan Drug Designation) (EMA, MAA) (Partnership) Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.